Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pearl-401
- Development stage
- Preclinical
- Lead developer
- PearlsInMires
- Modality
- Small Molecules
01
Overview
Pearl-401 is a preclinical-stage small molecule therapeutic being developed by the biotechnology company PearlsInMires. The drug is designed to target macrophages (Mφ) as a host-directed therapy for the treatment of infectious diseases. According to company pipeline information, Pearl-401 is part of a series of assets for which patent applications are expected to be completed by 2025. While the specific molecular target within the macrophage or the exact infectious indications have not been publicly detailed, the program focuses on modulating immune cell function to combat pathogens.
- Other names
- Pearl-401Pearl401Pearl 401
Beyond the preview
Go deeper on Pearl-401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pearl-401.